Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IPR-179

            Therapeutic Area: Neurology Product Name: ACT-03

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2021

            Details:

            The study results show that the ACT-03, when administered in animal models over one week, can slow the progression of the disease by reducing the severity and number of spontaneous seizures (up to seven weeks after initial drug administration).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: LifeArc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 18, 2021

            Details:

            The collaboration focuses on the discovery of novel selective small molecular modulators of a specific two-pore potassium ion target, identified as likely to be involved in neurological pathogenesis, and has now progressed to the hit-to-lead optimization phase.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: $161.5 million Upfront Cash: $7.0 million

            Deal Type: Collaboration December 21, 2020

            Details:

            The deal will leverage Icagen’s expertise in small molecule therapeutics targeting transmembrane proteins, utilising the company’s discovery technology to identify and develop inhibitors of a ‘specific genetically-validated molecular target’ relevant to neurological diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): C9orf2 -ALS

            Therapeutic Area: Neurology Product Name: C9orf2 -ALS

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Vida Ventures LLC

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing December 14, 2020

            Details:

            Funding supports pre-clinical and clinical development of proprietary RNA-targeting systems delivered via gene therapy for treating genetic diseases such as Huntington’s disease, myotonic dystrophy type 1, genetic ALS, and retinal disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Third Rock Ventures

            Deal Size: $81.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing December 10, 2020

            Details:

            The Series A will support Faze’s preclinical research in two initial therapeutic focus areas – ALS and myotonic dystrophy type 1 (DM1) – as well as research to explore condensate biology in other disease areas.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV-mediated gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: UCB Pharma S.A.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 12, 2020

            Details:

            New collaboration with Lacerta Therapeutics underlines UCB’s strategic focus in gene therapy to fulfil its Patient Value Ambition. New R&D collaboration with Lacerta Therapeutics provides access to a novel gene therapy program and proprietary AAV capsids.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $2,100.0 million Upfront Cash: $50.0 million

            Deal Type: Collaboration October 28, 2020

            Details:

            Insitro will apply its proprietary platform, the insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. BMS will be responsible for clinical development and regulatory submissions and commercialization activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Funding October 08, 2020

            Details:

            Knopp has developed a discovery platform of molecules directed to a non-opioid biological target linked to chronic pain caused by nerves damage. The drug target is Kv7.2/7.3 which regulates the flow of electrically charged ions required to modulate the excitability of cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibody therapeutics

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Casdin Capital

            Deal Size: $25.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 29, 2020

            Details:

            The Series A Financing positions the company for rapid scaling of its novel platform and advancing its portfolio of innovative antibody therapeutics for veterinary use.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

            Deal Size: $29.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 23, 2020

            Details:

            The company’s therapeutic platform is uniquely positioned to discover and develop novel small molecule drugs that can both increase autophagy to more rapidly clear toxic proteins and attenuate the production of neurotoxic proteins.

            PharmaCompass